ADC Innovative Drugs: Precision Targeted Chemotherapy Advances to a Large Anti-Tumor Drug Platform

English summary

### ADC Innovative Drugs: Precision Targeted Chemotherapy Advances to a Large Anti-Tumor Drug Platform Time: 2026-07-29 17:09:43 Content: ADC has once again become a focus in the innovative drug industry. According to GSK's public plan, the company accelerated Phase III clinical advancement in 2026, with two ADCs licensed from Hansoh Pharma playing important roles. The B7-H4 ADC, morzetzumab ravtansine (targeting B7-H4), plans to initiate five Phase III studies. The B7-H3 ADC, rifutuzumab ravtansine (targeting B7-H3), is expanding to small cell lung cancer, prostate cancer, and various solid tumors. The ADC industry is no longer staying at early response rates and proof of concept, but has entered a new stage centered on survival benefits, indication expansion, and large-scale Phase III clinical trials. Today we focus on interpreting ADC innovative drugs. What is ADC exactly? ADC stands for antibody-drug conjugate, which can be understood as a precision delivery chemotherapy system. It consists of three parts: an antibody that recognizes tumor cells, a linker connecting the antibody and the drug, and a highly active payload that kills tumor cells. ...